Analytical Data
-
Gene name
BTG3
- Application
-
Alternative Names
Abundant in neuroepithelium area Protein; ANA; BTG family member 3; Btg3; BTG3_HUMAN; Protein BTG3; Protein Tob5
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q14201
-
Expression Region
1-252aa
-
AA Sequence
MKNEIAAVVF FFTRLVRKHD KLKKEAVERF AEKLTLILQE KYKNHWYPEK PSKGQAYRCI RVNKFQRVDP DVLKACENSC ILYSDLGLPK ELTLWVDPCE VCCRYGEKNN AFIVASFENK DENKDEISRK VTRALDKVTS DYHSGSSSSD EETSKEMEVK PSSVTAAASP VYQISELIFP PLPMWHPLPR KKPGMYRGNG HQNHYPPPVP FGYPNQGRKN KPYRPIPVTW VPPPGMHCDR NHWINPHMLA PH
-
Molecular Weight
29.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BTG3, or B-cell translocation gene 3, is a member of the BTG/Tob family of proteins, which are known for their roles in regulating cell proliferation, differentiation, and apoptosis. Emerging evidence has positioned BTG3 as a potential tumor suppressor implicated in various malignancies, including breast and prostate cancers. Its expression levels are often found to be downregulated in tumor tissues, suggesting its role in maintaining normal cellular functions. Research has illuminated BTG3's involvement in several cellular pathways, particularly those related to cell cycle regulation and apoptosis, underscoring the necessity for further understanding its molecular mechanisms. Recent studies have utilized recombinant protein technology to produce BTG3 for structural and functional analyses. This approach facilitates not only the exploration of BTG3’s biochemical properties but also its interactions with other cellular components, which can assist in elucidating its role in oncogenesis. Furthermore, as the scientific community continues to seek novel therapeutic targets for cancer treatment, BTG3’s potential as a biomarker and therapeutic target is garnering significant interest, highlighting the importance of ongoing research into its functions and associated biological pathways.
